Generali Investments CEE investicni spolecnost a.s. Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Generali Investments CEE investicni spolecnost a.s. purchased a new position in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,300 shares of the company’s stock, valued at approximately $220,000.

A number of other large investors have also bought and sold shares of MRNA. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after buying an additional 388 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MRNA shares. UBS Group reduced their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $60.63.

Moderna Stock Performance

Shares of MRNA stock opened at $35.61 on Monday. The firm has a market cap of $13.74 billion, a price-to-earnings ratio of -3.84 and a beta of 1.86. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The firm’s 50-day simple moving average is $36.60 and its two-hundred day simple moving average is $48.77.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.